Sex chromosome aneuploidies (SCAs), including Klinefelter syndrome/47,XXY, Trisomy X/47,XXX, 47,XYY syndrome, and 48,XXYY syndrome, are the most prevalent supernumerary chromosomal conditions, occurring collectively in approximately one of 500 live births. Clinical phenotypes are highly variable in these conditions, often with mild dysmorphic features or neurodevelopmental involvement, resulting in only 10%-25% lifetime ascertainment (Abramsky & Chapple, 1997). Historically, prenatal SCA diagnoses accounted for 10% or less of SCA cases and were often incidental findings following CVS or amniocentesis for advanced maternal age, and the majority of SCA diagnoses occurred in the postnatal period during clinical evaluations for neurodevelopmental, medical, or infertility concerns (Bojesen et al., 2003). The initiation of cell-free fetal DNA screening, commonly referred to as noninvasive prenatal screening (NIPS), in 2012 and subsequent adoption into standardized obstetric care, has drastically changed the landscape